Business Wire

Merz Pharma: Xeomin® (incobotulinumtoxinA) Receives European Approval for Treatment of Chronic Sialorrhea in Adults

Share

Merz, a global leader in neurotoxin therapy, announced today the European approval of Xeomin® (incobotulinumtoxinA) for the symptomatic treatment of chronic sialorrhea (drooling) due to neurological disorders in adult patients.1 Xeomin® is the first and only neurotoxin with this approved indication in the EU, which follows the US FDA approval in July 2018.2

“At Merz, we are committed to bringing more good days to patients living with severe neurological disorders,” stated Stefan Brinkmann, Managing Director and Region Head EMEA at Merz. “We are confident that this new treatment option can help improve quality of life for sialorrhea patients, as well as for their relatives and caregivers. In many European countries, an approved medication for sialorrhea treatment in adults has not been available before now.”

Sialorrhea is a common but undertreated symptom accompanying neurological conditions such as Parkinson's disease, acquired brain injury, amyotrophic lateral sclerosis (ALS), cerebral palsy (CP) or stroke. Patients who experience sialorrhea suffer from a negative impact on activities of daily living, as well as social stigma and impaired quality of life. Left untreated, sialorrhea could be associated with perioral skin breakdown and pain around the mouth, choking, speech disorder, dehydration and aspiration pneumonia.3

Xeomin® is the first and only neurotoxin with this approved indication in the EU. This is the fourth therapeutic indication for Xeomin®, which was first introduced in 2005 in Germany and was approved in 13 EU member states in 2007 for the treatment of cervical dystonia and blepharospasm in adult patients. In 2009, Xeomin® received approval for the treatment of upper limb spasticity in adult patients. Xeomin® is approved in 31 EU/EEA member states for the treatment of different neurological indications and is registered in more than 60 countries worldwide.

About the SIAXI Study

The approval of Xeomin® for adult patients with sialorrhea by European authorities is based on a Phase III, randomized, double-blind, placebo-controlled, multicenter 184 patient trial. Both co-primary endpoints were successfully achieved. A statistically significant improvement was observed in change in unstimulated salivary flow rate (uSFR) and Global Impression of Change Scale (GICS), both at week four as compared to baseline pre-injection for subjects administered 100 U incobotulinumtoxinA vs. placebo (p=0.004 and p=0.002, respectively). GICS is a commonly used rating system for treatments of neurological disorders by clinicians. Overall frequency of adverse events was similar between placebo and treatment groups with no new or unexpected adverse events reported. Subjects enrolled in the study received placebo (n=36), incobotulinumtoxinA 75 U (n=74), or incobotulinumtoxinA 100 U (n=74). More detailed information about the study results can be found here.

About Xeomin ® (incobotulinumtoxinA)

Xeomin® (incobotulinumtoxinA) is a purified neurotoxin type A (150kD) free from complexing proteins that prevents the release of the neurotransmitter acetylcholine from nerve endings at muscles and salivary glands. This prescription medicine is used intramuscularly to treat increased muscle stiffness, e.g. in the arm or shoulder of adults with upper limb spasticity, or abnormal head position that happens with cervical dystonia (spasmodic torticollis) in adults, and to treat abnormal spasm of the eyelids (blepharospasm). The mode of action is similar in salivary glands by reducing saliva production after injection thereby reducing the frequency and severity of sialorrhea. IncobotulinumtoxinA is a highly potent active ingredient. Safety instructions, warnings and typical side effects for this agent should be taken into consideration.1

About Merz

Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately-held for more than 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetics products across the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2017/18, Merz generated revenue of EUR 1.024,4 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.

Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KgaA.

1 Product information Xeomin, May 2019

2 US Prescribing Information Xeomin, May 2019

3 McGeachan AJ et al. Pract Neurol 2017, 17:96-103

Contact information

Media Contact
Merz Pharma GmbH & Co. KGaA
Global Communications
Mariana Smith Bourland
Phone: +49 151 4249 1466
Email: mariana.smith@merz.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acrisure and Tulco Unveil Altway Insurance19.9.2019 16:00:00 CESTPress release

Top 10 global insurance broker Acrisure and leading investment company Tulco Holdings unveils Altway Insurance, a direct-to-consumer brokerage platform which is fully supported by artificial intelligence. Altway Insurance represents a unique blend of a world-class AI firm matched with an insurance broker with an equally world-class distribution network. Additionally, Google Cloud is working closely with the company on how to integrate Google's most cutting-edge AI technology into new AI applications. Tulco Chairman and CEO Thomas Tull said, “While there has been substantial investment to fuse technology and insurance, today, there remains a massive and unmet opportunity to truly create the broker of the future. To meet that opportunity, we're thrilled to combine the AI and analytics leadership of Tulco with the phenomenal growth and global distribution power of Acrisure.” Underlying Altway is the unique combination of Acrisure and Tulco. Acrisure delivers high quality insurance service

Mindbreeze recognized once again as a Leader in the 2019 Gartner Magic Quadrant for Insight Engines19.9.2019 15:20:00 CESTPress release

Mindbreeze, a leading global provider of appliances and cloud services for information insight and applied artificial intelligence with a focus on knowledge management for international companies, announced today that the company has been positioned by Gartner, Inc. as a Leader in the 2019 Magic Quadrant for Insight Engines. A complimentary copy of the report can be accessed from the Mindbreeze website “Mindbreeze enables our customers and their employees to garner and leverage crucial insights from their data. We work directly with our customers in this innovative field to bring meaning and value to their information assets that take us to the next level together,” comments Daniel Fallmann, Mindbreeze CEO and founder. “We believe this recognition further validates Mindbreeze’s success in the AI and knowledge management industry, as enterprises achieve ideal results using our unique and innovative solution.” Download the 2019 Magic Quadrant for Insight Engines now Many well-known custo

Amazon Co-founds The Climate Pledge, Setting Goal to Meet the Paris Agreement 10 Years Early19.9.2019 15:15:00 CESTPress release

Today, Amazon (NASDAQ: AMZN) and Global Optimism announced The Climate Pledge, a commitment to meet the Paris Agreement 10 years early. Amazon today becomes the first signatory of this pledge. The Climate Pledge calls on signatories to be net zero carbon across their businesses by 2040—a decade ahead of the Paris Accord’s goal of 2050. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005609/en/ Companies that sign The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis; Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon emission elimination strategies; Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially-beneficial offsets to achieve net zero annual carbon emissions by 2040. “We’re done b

In Impact Investing First, LeapFrog Announces Audit on Impact Principles, Achieving Top Rating19.9.2019 15:02:00 CESTPress release

LeapFrog Investments today became the first impact investor globally to announce the results of an independent audit of its impact against the Operating Principles for Impact Management, new industry standards developed by the IFC in consultation with leading impact investors and other stakeholders. Launched in April, the Principles provide common disciplines for management of investments for impact, helping to ensure authenticity and high standards of measurement. In the independent audit by Tideline, a leading US impact advisory consultancy, LeapFrog was assessed as an “Exemplification of industry best practice,” with its Impact Measurement and Management (IMM) system achieving “an advanced level of alignment across the board for all nine of the Principles.” Tideline concluded that “LeapFrog’s IMM comprehensively addresses and exceeds the implementation guidance provided by the IFC and has been refined and strengthened over the course of several funds.” “The impact investing industry

Andersen Global Expands Reach in London19.9.2019 13:30:00 CESTPress release

Andersen Global continues its expansion in the UK as Miles Dean, Zoe Wyatt and their team join the Andersen Tax LLP team in the UK. This addition brings further depth to the group in London and enhances the team’s ability to work with clients holistically and provide best-in-class, seamless service. Andersen Global has a presence in five locations in the UK through its member and collaborating firms. Miles and Zoe previously worked at Milestone which was founded by Miles Dean in 2008, with Zoe Wyatt joining as a partner in 2015. As part of Andersen Tax LLP, these partners will continue to provide a broad range of international tax services to corporations and private clients, investment funds and real estate investors and developers. Milestone signed a collaboration agreement with Andersen Global in 2018 and the positive impact of this relationship has led to Miles, Zoe and their team now joining the Andersen Global member firm in the UK. “It was so important to us to ensure we are pos

CGLytics and Glass Lewis Set a New Standard for Transparency in Equity-based Compensation19.9.2019 13:15:00 CESTPress release

CGLytics, a leading global provider of governance data and analytics, and Glass Lewis, the world’s leading independent provider of governance and engagement support services, today announced the launch of Glass Lewis’ Equity Compensation Model (ECM) - a powerful new application for assessing U.S. equity-based compensation plans, available exclusively via CGLytics. This new application provides invaluable intelligence with year-round, on-demand access to Glass Lewis’ methodology which is used to evaluate the overall favorability of current and future equity plans, including tests against 11 key criteria. Companies and investors can now instantly test, review and adjust the same individual inputs as Glass Lewis’ analysts to ensure the best compensation, engagement and voting outcomes for their respective sides. The ECM provides companies with immediate and proactive insight into the concerns regarding current and future equity plans, which Glass Lewis highlights to more than 1,300 invest